

**UNITED STATES DEPARTMENT OF COMMERCE****United States Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
09/405,735	09/24/99	PIER	6080177155

HM11/0808

EXAMINER
GHASHGHAEI, F

HELEN C LOCKHART
WOLF GREENFIELD & SACKS P C
600 ATLANTIC AVENUE
BOSTON MA 02210

ART UNIT
1656PAPER NUMBER
10

DATE MAILED: 08/08/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary	Application No.	Applicant(s)
	09/405,735	PIER, GERALD B.
	Examiner Fariba Ghashghaee	Art Unit 1656

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

卷之三

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on ____.

2a) This action is **FINAL**. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-68 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) _____ is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claims 1-68 are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are objected to by the Examiner.

11) The proposed drawing correction filed on _____ is: a) approved b) disapproved.

12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. ____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

15) Notice of References Cited (PTO-892) 18) Interview Summary (PTO-413) Paper No(s). _____
16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 19) Notice of Informal Patent Application (PTO-152)
17) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 20) Other: _____

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-13 are drawn to a method for upregulating CFTR expression in a tissue of a subject, classified in class 435, subclass 69.1
- II. Claims 14-43 are drawn to therapeutic compositions comprising a CFTR expression regulator, classified in class 424, subclass 418.
- III. Claims 44-53 are drawn to a method of treatment, classified in class 514, subclass 851.
- IV. Claims 54-68 are drawn to a composition comprising a covalent conjugate of an anti-pseudomonas drug and a cystic fibrosis transmembrane conductance regulator, classified in class 424, subclass 418.

Inventions are distinct, each from the other because of the following reasons:

Inventions of group I and II are related as process of making and product made.

The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case The products could be made by many different methods which are well known in gene therapy.

Inventions of group I and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP §

808.01). In the instant case the different inventions of group I could be used for different use, for example it can be used for different immunodeficiency diagnostic purposes or the protein replacement therapy in which the CFTR protein in an appropriate vehicle is delivered to the cell.

Inventions of groups I and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions of group IV could be used for different purposes such as making pharmaceutical compositions.


Inventions of group II and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the products of group II could be used for treating any immunodeficiency including CFTR.

Inventions of group II and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions of group II could be used for many different immunodeficiency conditions whereas the inventions of group IV is specifically used for the pseudomonal infections, because it has anti-pseudomonal drug.


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones can be reached on (703)308-1152. The fax phone numbers for the organization where this application or proceeding is assigned are (703)305-3014 for regular communications and (703)305-3014 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703)308-0196.

Fariba Ghashghaei



June 18, 2001



KENNETH R. HORLICK, Ph.D.
KENNETH R. HORLICK
PRIMARY EXAMINER 6/19/01
GROUP 1600



Creation date: 10-10-2003

Indexing Officer: CCOUNTISS - CORY COUNTISS

Team: OIPEBackFileIndexing

Dossier: 09405735

Legal Date: 01-04-2002

No.	Doccode	Number of pages
1	LET.	1
2	A...	1
3	REM	1

Total number of pages: 3

Remarks:

Order of re-scan issued on